Search
Galiximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Lexibulin
go.drugbank.com/drugs/DB05147InvestigationalCYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias
Categories: Heterocyclic Compounds, 1-RingNP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this
Fosfructose
go.drugbank.com/drugs/DB13863InvestigationalSynonyms: 1,6-di-O-phosphono-D-fructose, D-fructose 1,6-bisphosphateCategories: Compounds used in a research, industrial, or household settingGlyphosate
go.drugbank.com/drugs/DB04539ExperimentalCategories: Compounds used in a research, industrial, or household setting, N-substituted GlycinesRhodamine 6G
go.drugbank.com/drugs/DB03825InvestigationalSynonyms: Basic red 1, CI basic red 1Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein substratesIroxanadine
go.drugbank.com/drugs/DB05444ExperimentalIt induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).
Categories: Heterocyclic Compounds, 1-RingTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingTariquidar
go.drugbank.com/drugs/DB06240InvestigationalCategories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingGI-5005
go.drugbank.com/drugs/DB05942InvestigationalGI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. … GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets.